{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:34:39Z","timestamp":1793885679031,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed as first-line chemotherapy; however, the efficacy of second-line chemotherapy remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated patients with malignant peritoneal mesothelioma who started first-line systemic chemotherapy with platinum plus pemetrexed between March 2007 and February 2019 at the National Cancer Center Hospital. Patients who received second-line chemotherapy after failure of platinum plus pemetrexed were identified. We evaluated the efficacy of first- and second-line chemotherapy, and explored the prognostic factors. Survival outcomes were estimated using the Kaplan\u2013Meier method, and between-group differences were compared using the log-rank test. Univariate and multivariate analyses were performed using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 54 and 26 patients received platinum plus pemetrexed as first- and second-line chemotherapy, respectively (gemcitabine in 12 patients; taxane, six; nivolumab, three; and others, five). In all patients, the median overall survival and progression-free survival after first-line chemotherapy were 16.6 and 7.3\u2009months, respectively. Among patients who received second-line chemotherapy, the median overall survival, progression-free survival, and second-line overall survival were 16.9, 3.2, and 9.9\u2009months, respectively. Patients who received \u22656\u2009cycles of platinum plus pemetrexed as first-line chemotherapy had longer overall survival after second-line chemotherapy than those who did not (hazard ratio, 0.23; 95% confidence interval: 0.06\u20130.82;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Second-line chemotherapy may be an option for refractory malignant peritoneal mesothelioma, especially in patients who have completed 6\u2009cycles of platinum plus pemetrexed as first-line chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08025-x","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T04:02:22Z","timestamp":1616212942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Rui","family":"Kitadai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,20]]},"reference":[{"issue":"3","key":"8025_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s10147-008-0839-2","volume":"14","author":"S Tanida","year":"2009","unstructured":"Tanida S, Kataoka H, Kubota E, Mori Y, Sasaki M, Ogasawara N, Wada T, Mizoshita T, Shimura T, Murakami K, Mizushima T, Hirata Y, Okamoto Y, Mabuchi M, Ebi M, Tanaka M, Kamiya T, Takahashi S, Joh T. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol. 2009;14(3):266\u20139. https:\/\/doi.org\/10.1007\/s10147-008-0839-2.","journal-title":"Int J Clin Oncol"},{"issue":"Suppl 1","key":"8025_CR2","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.21037\/tlcr.2019.12.15","volume":"9","author":"A Greenbaum","year":"2020","unstructured":"Greenbaum A, Alexander HR. Peritoneal mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S120\u2013s32. https:\/\/doi.org\/10.21037\/tlcr.2019.12.15.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"8025_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18(6):985\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdl345.","journal-title":"Ann Oncol"},{"issue":"6","key":"8025_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/ctrv.2001.0232","volume":"27","author":"AJ Witkamp","year":"2001","unstructured":"Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev. 2001;27(6):365\u201374. https:\/\/doi.org\/10.1053\/ctrv.2001.0232.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"8025_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8025_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","volume":"7","author":"PA J\u00e4nne","year":"2005","unstructured":"J\u00e4nne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40\u20136. https:\/\/doi.org\/10.3816\/CLC.2005.n.020.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"8025_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64(2):211\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2008.08.013.","journal-title":"Lung Cancer"},{"issue":"11","key":"8025_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/jjco\/hyz104","volume":"49","author":"Y Nagata","year":"2019","unstructured":"Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, Amano K, Kato K, Hamaguchi T, Shimada Y, Saruta M, Boku N. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma. Jpn J Clin Oncol. 2019;49(11):1004\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyz104.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"8025_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-0031-1272874","volume":"32","author":"NP Campbell","year":"2011","unstructured":"Campbell NP, Kindler HL. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011;32(1):102\u201310. https:\/\/doi.org\/10.1055\/s-0031-1272874.","journal-title":"Semin Respir Crit Care Med"},{"issue":"2","key":"8025_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"5","key":"8025_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.21037\/jgo.2017.08.01","volume":"8","author":"A Garc\u00eda-Fadrique","year":"2017","unstructured":"Garc\u00eda-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ. Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol. 2017;8(5):915\u201324. https:\/\/doi.org\/10.21037\/jgo.2017.08.01.","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"8025_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jclinpath-2014-202465","volume":"67","author":"M Takeda","year":"2014","unstructured":"Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Nakai T, Iizuka N, Maruyama H, Ohbayashi C. Comparison of genomic abnormality in malignant mesothelioma by the site of origin. J Clin Pathol. 2014;67(12):1038\u201343. https:\/\/doi.org\/10.1136\/jclinpath-2014-202465.","journal-title":"J Clin Pathol"},{"issue":"6","key":"8025_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ejso.2006.03.009","volume":"32","author":"R Garcia-Carbonero","year":"2006","unstructured":"Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):676\u201381. https:\/\/doi.org\/10.1016\/j.ejso.2006.03.009.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"8025_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","volume":"63","author":"J Stebbing","year":"2009","unstructured":"Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JPC. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63(1):94\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2008.04.001.","journal-title":"Lung Cancer"},{"issue":"1","key":"8025_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/1756-0500-5-482","volume":"5","author":"A Bearz","year":"2012","unstructured":"Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, Favaretto A, Gregorc V, Berretta M, Santarossa S, Berto E, Tirelli U. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes. 2012;5(1):482. https:\/\/doi.org\/10.1186\/1756-0500-5-482.","journal-title":"BMC Res Notes"},{"issue":"6","key":"8025_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/annonc\/mdi187","volume":"16","author":"C Manegold","year":"2005","unstructured":"Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16(6):923\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdi187.","journal-title":"Ann Oncol"},{"issue":"12","key":"8025_CR17","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","volume":"85","author":"JP van Meerbeeck","year":"1999","unstructured":"van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz MA, Giaccone G, European Organization for Research Treatment of Cancer Lung Cancer Cooperative Group. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer lung Cancer cooperative group. Cancer. 1999;85(12):2577\u201382. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S.","journal-title":"Cancer."},{"issue":"3","key":"8025_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/annonc\/mdf046","volume":"13","author":"DA Vorobiof","year":"2002","unstructured":"Vorobiof DA, Rapoport BL, Chasen MR, Abratt RP, Cronje N, Fourie L, McMichael G, Hacking D. Malignant pleural mesothelioma: a phase II trial with docetaxel. Ann Oncol. 2002;13(3):412\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdf046.","journal-title":"Ann Oncol"},{"issue":"18","key":"8025_CR19","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y. Clinical efficacy and safety of Nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0103.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"8025_CR20","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, Klomp H, Hartemink K, Burgers S, Buikhuisen W, Baas P. Programmed death 1 blockade with Nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1569\u201376. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.038.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"8025_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260\u201370. https:\/\/doi.org\/10.1016\/S2213-2600(18)30420-X.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"8025_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Morra A, Giannarelli D, Amato G, D'Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R, Altomonte M, di Giacomo AM, Maio M. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(18)30151-6.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"8025_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","volume":"19","author":"DA Fennell","year":"2018","unstructured":"Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J, Ottensmeier C, Barnes D, Hill S, Kalevras M, Maishman T, Griffiths G. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018;19(1):233. https:\/\/doi.org\/10.1186\/s13063-018-2602-y.","journal-title":"Trials."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-021-08025-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T04:03:47Z","timestamp":1616213027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08025-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,20]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8025"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08025-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-139312\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,20]]},"assertion":[{"value":"1 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the National Cancer Center Research Ethics Review Committee at National Cancer Center Hospital, Tokyo, Japan (approval numbers: 2012\u2013335 and 2017\u2013229). Research was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the Institutional Review Board of National Cancer Center Hospital owing to the retrospective nature of the study. Patients could refuse to participate in this study by an opt-out form on the website of our institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}